Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways
In conclusion, our study has provided initial data of a novel low MW compound, Anti-b, designed and synthesised to target mTOR protein directly. Our results indicate that Anti-b may represent a novel class of drugs for the treatment of hyperlipidemia and hepatic steatosis.
Authors
- Ping Pang (ORCID: https://orcid.org/0000-0003-4143-3411)
- Jinglun Song
- Yüting Xiong (ORCID: https://orcid.org/0000-0002-2628-4932)
- Tianqi Duo (ORCID: https://orcid.org/0000-0001-9211-4125)
- Yu Bian (ORCID: https://orcid.org/0000-0002-6741-1192)
- Chunlei Wang (ORCID: https://orcid.org/0000-0002-7675-8921)
- Tengfei Pan
- Weitao Jiang (ORCID: https://orcid.org/0000-0002-9222-2844)
- Xinyue Zhang (ORCID: https://orcid.org/0000-0001-6503-2378)
- Baofeng Yang (ORCID: https://orcid.org/0000-0002-0125-1608)
- Xue Kong
- Yang Yang (ORCID: https://orcid.org/0000-0002-8190-1825)
- Han Wu (ORCID: https://orcid.org/0000-0002-6190-7939)
- Yuning Zhang (ORCID: https://orcid.org/0000-0001-8867-8235)
- Ling-Hua Zeng
- Feng Zhang
- Zhuo Wang (ORCID: https://orcid.org/0009-0006-3418-3118)
Institutions
- Harbin Medical University (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1111/bph.17397
- Citations
- 11
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 2.57
Funders
- National Natural Science Foundation of China